Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer

被引：0
|
作者：
Ursina R. Teitelbaum
Daniel G. Haller
机构：
[1] University of Pennsylvania,Division of Hematology
来源：
Nature Reviews Clinical Oncology | 2009年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic colorectal cancer. This paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens.
引用
收藏
页码：250 / 251
页数：1
相关论文
共 50 条
  • [1] Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
    Teitelbaum, Ursina R.
    Haller, Daniel G.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (05) : 250 - 251
  • [2] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
    Grothey, Axel
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (01): : 10 - 11
  • [3] A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer
    Axel Grothey
    [J]. Nature Clinical Practice Oncology, 2009, 6 : 10 - 11
  • [4] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    J Cassidy
    S Clarke
    E Díaz-Rubio
    W Scheithauer
    A Figer
    R Wong
    S Koski
    K Rittweger
    F Gilberg
    L Saltz
    [J]. British Journal of Cancer, 2011, 105 : 58 - 64
  • [5] XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
    Cassidy, J.
    Clarke, S.
    Diaz-Rubio, E.
    Scheithauer, W.
    Figer, A.
    Wong, R.
    Koski, S.
    Rittweger, K.
    Gilberg, F.
    Saltz, L.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 58 - 64
  • [6] Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study
    Rothenberg, M. L.
    Cox, J. V.
    Butts, C.
    Navarro, M.
    Bang, Y. -J.
    Goel, R.
    Gollins, S.
    Siu, L. L.
    Laguerre, S.
    Cunningham, D.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (10) : 1720 - 1726
  • [7] Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer
    Shi, Sha
    Lu, Kemei
    Gao, Hui
    Sun, Huidong
    Li, Senlin
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (09): : 1971 - 1977
  • [8] FOLFOX-4 Regimen as a First-line Therapy for Cuban Patients with Metastatic Colorectal Cancer
    Lami, Leonardo
    Areces, Fernando
    Lence, Juan J.
    Arbesu, Maria A.
    [J]. MEDICC REVIEW, 2009, 11 (03) : 34 - 38
  • [9] A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN
    Darba, J.
    Restovic, G.
    Ramirez de Arellano, A.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A467 - A467
  • [10] Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
    Jeon, Eun Kyoung
    Hong, Sook Hee
    Kim, Tae Hee
    Jung, Seung Eun
    Park, Ji Chan
    Won, Hye-Sung
    Ko, Yoon-Ho
    Rho, Sang Young
    Hong, Young Seon
    [J]. CANCER RESEARCH AND TREATMENT, 2011, 43 (03): : 148 - 153
12345